Genmab A/S/DKr GMAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.
- Ticker
- DKr GMAB
- Sector
- Health
- Primary listing
- CSE
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab A/S Metrics
BasicAdvanced
kr 129B
26.71
kr 81.42
0.69
-
Price and volume
Market cap
kr 129B
Beta
0.69
52-week high
kr 2,257.00
52-week low
kr 1,512.00
Average daily volume
116K
Financial strength
Current ratio
2.457
Quick ratio
2.441
Long term debt to equity
83.28
Total debt to equity
88.518
Interest coverage (TTM)
4.96%
Profitability
EBITDA (TTM)
8,862.51
Gross margin (TTM)
93.03%
Net profit margin (TTM)
19.08%
Operating margin (TTM)
32.29%
Effective tax rate (TTM)
13.02%
Revenue per employee (TTM)
kr 8,495,650
Management effectiveness
Return on assets (TTM)
8.79%
Return on equity (TTM)
14.00%
Valuation
Price to earnings (TTM)
26.714
Price to revenue (TTM)
5.039
Price to book
21.7
Price to tangible book (TTM)
-39.53
Price to free cash flow (TTM)
23.983
Free cash flow yield (TTM)
4.17%
Free cash flow per share (TTM)
90.689
Growth
Revenue change (TTM)
22.26%
Earnings per share change (TTM)
-36.79%
3-year revenue growth (CAGR)
18.55%
10-year revenue growth (CAGR)
34.68%
3-year earnings per share growth (CAGR)
5.57%
10-year earnings per share growth (CAGR)
22.19%
Bulls say / Bears say
Net sales of DARZALEX® in Q2 2026 totaled USD 4.207 billion, underscoring strong market adoption (Reuters)
Royalties from DARZALEX® reached USD 8.17 billion in the first six months of 2026, up 21% year over year, driven by high demand across the U.S. and international markets (Reuters)
Genmab raised its full-year 2026 revenue guidance to USD 4.325–4.525 billion from USD 4.065–4.395 billion, reflecting management’s confidence in sustained growth momentum (Reuters)
Genmab lifted its 2026 adjusted operating expenses guidance to USD 2.81–2.95 billion from USD 2.71–2.91 billion, a 3.6% increase at the midpoint, indicating rising costs that may pressure margins (SEC)
Global net product sales of Tivdak® remained flat at USD 45 million in Q2 2026, matching the prior-year period and suggesting limited commercial traction for this oncology asset (SEC)
Research and development expenses climbed 24% to USD 899 million in H1 2026, driven by higher clinical development costs for petosemtamab and Rina-S, which could weigh on near-term profitability (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
No upcoming events
Funds containing Genmab A/S
AllUSDEURGBP
Fund name | Fund size | DKr GMAB weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.57% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.57% |
iShares Healthcare Innovation£DRDR | £1B | 1.57% |
iShares STOXX Europe 600 Health Care€EXV4 | €711M | 1.09% |
iShares MSCI Europe Health Care Sector€ESIH | €872M | 0.94% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.